Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE (NASDAQ: BNTX) generates frequent news flow as a global next generation immunotherapy company focused on oncology, mRNA technologies and COVID-19 vaccines. Its updates often cover progress across a diversified oncology pipeline that includes mRNA cancer immunotherapies, next-generation immunomodulators, antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cell therapies, as well as developments in its mRNA vaccine programs for infectious diseases.
Investors following BioNTech news can expect regular announcements on clinical trial milestones in major tumor types such as lung, breast, gynecologic, gastrointestinal and genitourinary cancers. Recent releases have highlighted late-stage data readouts and trial initiations for investigational agents like pumitamig (a PD-L1xVEGF-A bispecific antibody co-developed with Bristol Myers Squibb) and gotistobart (a CTLA-4–targeting Treg modulator), including Phase 2 and Phase 3 results in indications such as triple-negative breast cancer and squamous non-small cell lung cancer.
BioNTech’s news stream also includes corporate and financial updates, such as quarterly results, guidance changes, and details of its cash and investment position. The company reports on its COVID-19 vaccine franchise, including launches of variant-adapted vaccines for specific vaccination seasons, and comments on how vaccine market dynamics affect revenues.
Another recurring theme in BNTX news is strategic transactions and partnerships. BioNTech has announced an all-stock acquisition of CureVac N.V. to strengthen its position in mRNA design, delivery formulations and manufacturing, and regularly issues releases on its collaboration with partners including Bristol Myers Squibb, Duality Biologics, OncoC4, Pfizer and others.
This news page aggregates these developments in one place, allowing readers to track BioNTech’s clinical progress, partnership activity, financial disclosures and strategic updates over time.
Pfizer and BioNTech announced the initiation of a Biologics License Application (BLA) with the FDA for their COVID-19 mRNA vaccine for individuals 16 years and older. This BLA submission follows the delivery of over 170 million doses under Emergency Use Authorization (EUA). The companies aim to secure full regulatory approval by submitting clinical trial data and manufacturing information on a rolling basis. A supplemental BLA will also be submitted to expand the EUA to include individuals aged 12 to 15, following the availability of required data.
Pfizer and BioNTech announced the initiation of a Biologics License Application (BLA) with the FDA for their mRNA COVID-19 vaccine for individuals aged 16 and older. This submission supports their ongoing Emergency Use Authorization (EUA) since December 2020, during which over 170 million doses have been delivered in the U.S. The BLA aims for full regulatory approval, with data submitted on a rolling basis. The companies also seek to expand the EUA to include ages 12 to 15, followed by a supplemental BLA once data for this age group is available.
On May 6, 2021, Pfizer and BioNTech announced a Memorandum of Understanding with the International Olympic Committee to provide COVID-19 vaccines to athletes participating in the Tokyo 2020 Olympic and Paralympic Games. The initial vaccine doses are expected to be delivered by the end of May, ensuring athletes receive both doses prior to arriving in Tokyo. This initiative aims to enhance the safety of the Games while demonstrating solidarity with host Japan. The vaccine is authorized for emergency use in individuals aged 16 and older but remains unlicensed by the FDA.
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) signed a Memorandum of Understanding with the IOC to donate COVID-19 vaccine doses to athletes participating in the Tokyo 2020 Olympic and Paralympic Games, starting July 23, 2021. Initial doses are set for delivery by the end of May. The agreement ensures that vaccine doses provided will not detract from national supply agreements. IOC President emphasized the donation's role in promoting safety and solidarity. Pfizer's Chairman stated that the initiative represents a unifying moment post-pandemic, while BioNTech's CEO highlighted the importance of vaccines for a successful Games.
BioNTech SE (Nasdaq: BNTX) will announce its Q1 2021 financial results on May 10, 2021. The company invites investors and the public to join a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) for the financial update and corporate insights. Access to the slide presentation and audio will be provided online.
BioNTech focuses on innovative immunotherapy solutions targeting serious diseases, leveraging advanced mRNA technology and collaborating with major pharmaceutical partners.
BioNTech (Nasdaq: BNTX) and Pfizer (NYSE: PFE) have submitted a variation for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA) for their vaccine COMIRNATY (BNT162b2) to extend its use for adolescents aged 12 to 15. This follows a pivotal Phase 3 clinical trial with 2,260 participants showing 100% vaccine efficacy and robust antibody responses. The companies also seek Emergency Use Authorization in the U.S. and plan similar submissions globally, aiming for broader vaccine access.
BioNTech (BNTX) and Pfizer announced an agreement to supply 100 million additional doses of COMIRNATY to the European Union, increasing total doses to 600 million for 27 member states. All doses are expected to be delivered in 2021. The European Commission exercised this option under an expanded Advanced Purchase Agreement signed on February 17, 2021. Pfizer plans to deliver 250 million doses in Q2, which is a 400% increase compared to Q1.
Pfizer and BioNTech announced updated results from their Phase 3 study of the COVID-19 vaccine, BNT162b2, indicating a 91.3% efficacy against symptomatic COVID-19 up to six months post-second dose. The vaccine demonstrated 100% effectiveness in preventing severe disease per CDC guidelines and 95.3% effectiveness according to FDA standards. Over 44,000 participants were evaluated for safety, with favorable outcomes reported. The companies plan to submit a Biologics License Application to the FDA soon, bolstering confidence in the vaccine's ability to combat variants.
Pfizer and BioNTech released updated topline results from their pivotal Phase 3 study on the BNT162b2 COVID-19 vaccine, reporting a 91.3% efficacy rate in preventing symptomatic COVID-19. The vaccine showed 100% effectiveness against severe disease according to the CDC and 95.3% against severe COVID-19 per the FDA. Safety data indicated a favorable profile from over 12,000 participants monitored for at least six months post-vaccination. These results bolster plans for a Biologics License Application to the FDA.
BioNTech (Nasdaq: BNTX) and Pfizer released positive results from a Phase 3 trial showing BNT162b2 vaccine achieved 100% efficacy in adolescents aged 12-15, exceeding the results of the 16-25 age group. The trial involved 2,260 participants, with no COVID-19 cases in the vaccinated group. The companies plan to submit the data to the FDA and EMA for Emergency Use Authorization expansion. Additionally, they initiated a Phase 1/2/3 study for children aged 6 months to 11 years, aiming to assess vaccine safety and immunogenicity.